Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$23.51
al cierre: Sep 15 EDT
$23.90
0.391.66%
Pre-comercialización: 5:01 AM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Moderna Inc ha un obiettivo di prezzo di consenso pari a $57, stabilito in base alle ultime valutazioni degli analisti di 27. Le ultime 3 valutazioni degli analisti sono state rilasciate da Leerink Partners, Barclays y B of A Securities il agosto 22, 2025, agosto 4, 2025 y julio 22, 2025. Con un obiettivo di prezzo medio di $23.67 tra le Leerink Partners, Barclays y B of A Securities, c'è un implicito -0.98% downside per Moderna Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Leerink Partners
Barclays
B of A Securities
JP Morgan
UBS
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Moderna
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/22/2025 | -37.24% | Leerink Partners | $18 → $15 | Maintains | Underperform | |||
08/04/2025 | 29.71% | Barclays | $40 → $31 | Maintains | Equal-Weight | |||
07/22/2025 | 4.6% | B of A Securities | $26 → $25 | Maintains | Underperform | |||
05/22/2025 | 8.79% | JP Morgan | $33 → $26 | Maintains | Underweight | |||
05/02/2025 | 192.89% | UBS | $78 → $70 | Maintains | Buy | |||
05/02/2025 | 67.36% | Barclays | $45 → $40 | Maintains | Equal-Weight | |||
05/02/2025 | 17.15% | RBC Capital | $32 → $28 | Maintains | Sector Perform | |||
05/02/2025 | 33.89% | Evercore ISI Group | $50 → $32 | Maintains | In-Line | |||
04/09/2025 | 33.89% | Morgan Stanley | $39 → $32 | Maintains | Equal-Weight | |||
03/21/2025 | 38.08% | JP Morgan | $40 → $33 | Maintains | Underweight | |||
03/13/2025 | 67.36% | Citigroup | → $40 | Initiates | → Neutral | |||
02/19/2025 | 226.36% | UBS | $96 → $78 | Maintains | Buy | |||
02/18/2025 | 67.36% | RBC Capital | $40 → $40 | Reiterates | Sector Perform → Sector Perform | |||
02/18/2025 | 88.28% | Barclays | $111 → $45 | Downgrade | Overweight → Equal-Weight | |||
02/11/2025 | 42.26% | B of A Securities | $41 → $34 | Maintains | Underperform | |||
01/29/2025 | 113.39% | Goldman Sachs | $99 → $51 | Downgrade | Buy → Neutral | |||
01/28/2025 | 314.23% | Goldman Sachs | $112 → $99 | Maintains | Buy | |||
01/27/2025 | 109.21% | Evercore ISI Group | $60 → $50 | Maintains | In-Line | |||
01/15/2025 | 59% | Morgan Stanley | $70 → $38 | Maintains | Equal-Weight | |||
01/13/2025 | 67.36% | RBC Capital | $50 → $40 | Maintains | Sector Perform | |||
01/08/2025 | 301.67% | UBS | $108 → $96 | Maintains | Buy | |||
12/18/2024 | — | Argus Research | — | Downgrade | Buy → Hold | |||
12/10/2024 | 71.55% | B of A Securities | → $41 | Reinstates | → Underperform | |||
11/26/2024 | 88.28% | JP Morgan | $59 → $45 | Maintains | Underweight | |||
11/25/2024 | 109.21% | RBC Capital | $62 → $50 | Maintains | Sector Perform | |||
11/18/2024 | 188.7% | Piper Sandler | $115 → $69 | Reiterates | Overweight → Overweight | |||
11/18/2024 | 142.68% | HSBC | → $58 | Upgrade | Hold → Buy | |||
11/15/2024 | 67.36% | Wolfe Research | → $40 | Initiates | → Underperform | |||
11/08/2024 | 159.41% | RBC Capital | $75 → $62 | Maintains | Sector Perform | |||
11/08/2024 | 364.44% | Barclays | $125 → $111 | Maintains | Overweight | |||
11/08/2024 | — | Needham | — | Reiterates | → Hold | |||
11/04/2024 | 146.86% | JP Morgan | $70 → $59 | Maintains | Underweight | |||
10/24/2024 | 351.88% | UBS | $140 → $108 | Maintains | Buy | |||
10/17/2024 | 130.13% | Bernstein | → $55 | Initiates | → Market Perform | |||
10/15/2024 | 130.13% | Jefferies | $65 → $55 | Maintains | Hold | |||
09/19/2024 | 213.81% | RBC Capital | $75 → $75 | Reiterates | Sector Perform → Sector Perform | |||
09/16/2024 | 481.59% | Goldman Sachs | $178 → $139 | Maintains | Buy | |||
09/16/2024 | 423.01% | Barclays | $155 → $125 | Maintains | Overweight | |||
09/13/2024 | 360.25% | B of A Securities | $130 → $110 | Maintains | Neutral | |||
09/13/2024 | 381.17% | Piper Sandler | $157 → $115 | Maintains | Overweight | |||
09/13/2024 | 151.05% | TD Cowen | $70 → $60 | Maintains | Hold | |||
09/13/2024 | 213.81% | RBC Capital | $90 → $75 | Maintains | Sector Perform | |||
09/13/2024 | 192.89% | JP Morgan | $88 → $70 | Downgrade | Neutral → Underweight | |||
09/13/2024 | 171.97% | Jefferies | $120 → $65 | Downgrade | Buy → Hold | |||
09/13/2024 | — | Oppenheimer | — | Downgrade | Outperform → Perform | |||
09/13/2024 | — | Needham | — | Reiterates | → Hold | |||
08/28/2024 | 243.1% | HSBC | → $82 | Upgrade | Reduce → Hold | |||
08/15/2024 | 268.2% | JP Morgan | $96 → $88 | Maintains | Neutral | |||
08/06/2024 | 234.73% | Deutsche Bank | $85 → $80 | Upgrade | Sell → Hold | |||
08/05/2024 | 276.57% | RBC Capital | $125 → $90 | Downgrade | Outperform → Sector Perform | |||
08/02/2024 | 423.01% | RBC Capital | $160 → $125 | Maintains | Outperform | |||
08/02/2024 | 644.77% | Goldman Sachs | $204 → $178 | Maintains | Buy | |||
08/02/2024 | 548.54% | Barclays | $168 → $155 | Maintains | Overweight | |||
08/02/2024 | 556.9% | Piper Sandler | $214 → $157 | Reiterates | Overweight → Overweight | |||
08/01/2024 | — | Needham | — | Reiterates | → Hold | |||
06/28/2024 | — | Needham | — | Reiterates | → Hold | |||
06/27/2024 | 795.4% | Piper Sandler | $214 → $214 | Reiterates | Overweight → Overweight | |||
06/27/2024 | 402.09% | Evercore ISI Group | $120 → $120 | Maintains | In-Line | |||
06/12/2024 | 301.67% | JP Morgan | $85 → $96 | Maintains | Neutral | |||
06/12/2024 | 648.95% | Oppenheimer | $163 → $179 | Maintains | Outperform | |||
06/03/2024 | 569.46% | RBC Capital | $135 → $160 | Maintains | Outperform | |||
06/03/2024 | — | Needham | — | Reiterates | → Hold | |||
05/14/2024 | 402.09% | Evercore ISI Group | → $120 | Initiates | → In-Line | |||
05/07/2024 | 531.8% | UBS | $143 → $151 | Maintains | Buy | |||
05/03/2024 | 343.51% | Canaccord Genuity | $91 → $106 | Maintains | Hold | |||
05/03/2024 | 464.85% | RBC Capital | $125 → $135 | Maintains | Outperform | |||
05/03/2024 | 582.01% | Oppenheimer | $142 → $163 | Maintains | Outperform | |||
05/02/2024 | — | Needham | — | Reiterates | → Hold | |||
04/11/2024 | — | Needham | — | Reiterates | → Hold | |||
04/09/2024 | 423.01% | Jefferies | → $125 | Reiterates | Buy → Buy | |||
03/28/2024 | 423.01% | RBC Capital | $125 → $125 | Reiterates | Outperform → Outperform | |||
03/28/2024 | — | Needham | — | Reiterates | → Hold | |||
03/15/2024 | 255.65% | JP Morgan | $90 → $85 | Maintains | Neutral | |||
02/26/2024 | 259.83% | HSBC | $75 → $86 | Downgrade | Hold → Reduce | |||
02/23/2024 | 423.01% | RBC Capital | $125 → $125 | Reiterates | Outperform → Outperform | |||
02/23/2024 | 280.75% | Canaccord Genuity | $82 → $91 | Maintains | Hold | |||
01/12/2024 | 423.01% | RBC Capital | $125 → $125 | Reiterates | Outperform → Outperform | |||
01/02/2024 | 494.14% | Oppenheimer | → $142 | Upgrade | Perform → Outperform | |||
12/01/2023 | 276.57% | JP Morgan | $93 → $90 | Maintains | Neutral | |||
11/29/2023 | 243.1% | Canaccord Genuity | → $82 | Initiates | → Hold | |||
11/03/2023 | 423.01% | RBC Capital | $180 → $125 | Maintains | Outperform | |||
11/03/2023 | 866.53% | Goldman Sachs | $269 → $231 | Maintains | Buy | |||
11/03/2023 | 188.7% | HSBC | $89 → $69 | Upgrade | Reduce → Hold | |||
11/02/2023 | — | Deutsche Bank | — | Downgrade | Hold → Sell | |||
09/13/2023 | 485.77% | Argus Research | $160 → $140 | Maintains | Buy | |||
08/04/2023 | 414.64% | Morgan Stanley | $128 → $123 | Maintains | Equal-Weight | |||
08/04/2023 | 527.62% | B of A Securities | $175 → $150 | Maintains | Neutral | |||
08/04/2023 | 694.98% | RBC Capital | $200 → $190 | Maintains | Outperform | |||
08/04/2023 | 423.01% | TD Cowen | $145 → $125 | Downgrade | Outperform → Market Perform | |||
08/03/2023 | 423.01% | Deutsche Bank | $200 → $125 | Downgrade | Buy → Hold | |||
07/24/2023 | 590.38% | TD Cowen | $175 → $165 | Maintains | Outperform | |||
07/24/2023 | — | William Blair | — | Initiates | → Market Perform | |||
07/14/2023 | 305.86% | HSBC | → $97 | Initiates | → Reduce | |||
07/11/2023 | 435.56% | Morgan Stanley | $153 → $128 | Maintains | Equal-Weight | |||
06/26/2023 | 699.16% | UBS | $221 → $191 | Upgrade | Neutral → Buy | |||
05/05/2023 | 707.53% | Morgan Stanley | $185 → $193 | Maintains | Equal-Weight | |||
04/26/2023 | — | Guggenheim | — | Initiates | → Neutral | |||
04/12/2023 | 485.77% | JP Morgan | $145 → $140 | Maintains | Neutral | |||
04/10/2023 | 506.69% | JP Morgan | $127 → $145 | Maintains | Neutral | |||
03/13/2023 | 653.14% | TD Cowen | $150 → $180 | Upgrade | Market Perform → Outperform |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Moderna (MRNA)?
El último precio objetivo de Moderna (NASDAQ:MRNA) fue comunicado por Leerink Partners el agosto 22, 2025. La firma de analistas fijó un precio objetivo para $15.00 que espera MRNA a fall dentro de 12 meses (un posible -37.24% downside). 38 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Moderna (MRNA)?
La última calificación de analistas para Moderna (NASDAQ:MRNA) fue proporcionada por Leerink Partners, y Moderna mantuvo su underperform calificación.
¿Cuándo se produjo la última revisión al alza de Moderna (MRNA)?
La última revisión al alza de Moderna Inc se produjo en noviembre 18, 2024, cuando HSBC elevó su precio objetivo a $58. HSBC anteriormente tenía a hold para Moderna Inc.
¿Cuándo fue la última revisión a la baja de Moderna (MRNA)?
La última revisión a la baja de Moderna Inc se produjo en febrero 18, 2025, cuando Barclays cambió su precio objetivo de $111 a $45 para Moderna Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Moderna (MRNA)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Moderna, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Moderna se registró el agosto 22, 2025, por lo que la próxima calificación estará disponible en torno al agosto 22, 2026.
¿Es correcta la calificación de los analistas sobre Moderna (MRNA)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Moderna (MRNA) fue un mantuvo con un precio objetivo de $18.00 a $15.00. El precio actual al que cotiza Moderna (MRNA) es de $23.90, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.